ImmunityBio, Inc. (NASDAQ: IBRX) reported Q1 EPS of ($0.62), $0.55 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $44.21 million versus the consensus estimate of $43.07 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.